NR1H4 and biliary liver cirrhosis: Indeed, the CC regulates (a) FXR and bile acid metabolism (targeted by FXR agonists), (b) FGF-21 (targeted by antifibrotic compounds in clinical development), and (c) PPAR, the target of elafibranor to treat primary biliary cholangitis.